Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4362 publications

Initial Consensus for the Management of Topical Steroid Withdrawal: A Delphi Study.

Initial Consensus for the Management of Topical Steroid Withdrawal: A Delphi Study.

Journal: Dermatitis : contact, atopic, occupational, drug
Published: October 15, 2025

Central Retinal Artery Occlusion Induced by Dupilumab: A Unique Manifestation of Eosinophilic Granulomatosis with Polyangiitis.

Central Retinal Artery Occlusion Induced by Dupilumab: A Unique Manifestation of Eosinophilic Granulomatosis with Polyangiitis.

Journal: Internal medicine (Tokyo, Japan)
Published: October 15, 2025

Successful treatment of solid facial edema with dupilumab: A case report.

Successful treatment of solid facial edema with dupilumab: A case report.

Journal: JAAD case reports
Published: October 13, 2025

Use of dupilumab in eczematous eruptions following hematopoietic cell transplantation.

Use of dupilumab in eczematous eruptions following hematopoietic cell transplantation.

Journal: JAAD case reports
Published: October 13, 2025

TWO CASES OF MPO-ANCA-POSITIVE EGPA WITH CHRONIC RHINOSINUSITIS SHOWING DIFFERENT RESPONSES TO MEPOLIZUMAB

TWO CASES OF MPO-ANCA-POSITIVE EGPA WITH CHRONIC RHINOSINUSITIS SHOWING DIFFERENT RESPONSES TO MEPOLIZUMAB

Journal: Arerugi = [Allergy]
Published: October 13, 2025

Immune checkpoint inhibitor-associated acquired reactive perforating collagenosis treated with dupilumab.

Immune checkpoint inhibitor-associated acquired reactive perforating collagenosis treated with dupilumab.

Journal: JAAD case reports
Published: October 13, 2025

Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: A case study.

Effective response to high-frequency and prolonged dupilumab therapy in severe refractory bullous pemphigoid: A case study.

Journal: Human vaccines & immunotherapeutics
Published: October 09, 2025

Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.

Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.

Journal: Italian journal of dermatology and venereology
Published: October 03, 2025

Type-2 immune skewing in patients with disseminated coccidioidomycosis.

Type-2 immune skewing in patients with disseminated coccidioidomycosis.

Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025

Historic Perspectives of Prurigo Nodularis.

Historic Perspectives of Prurigo Nodularis.

Journal: Clinics in dermatology
Published: October 03, 2025

Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months.

Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months.

Journal: Journal of drugs in dermatology : JDD
Published: October 02, 2025

INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema.

INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema.

Journal: Journal of drugs in dermatology : JDD
Published: October 02, 2025
Showing 1-12 of 4,362

Last Updated: 10/31/2025